---
canonical_url: https://www.stockexpertai.com/earnings/cl
last_updated: 2026-05-05T20:11:30.242Z
---

# Colgate-Palmolive Company (CL) Q1 FY2027 Earnings Preview

> This content was automatically generated with FMP live data + Q1 FY2026 earnings call transcript. Generated: 2026-05-05T20:11:29.899Z. Educational tool, not investment advice.

---

## Quick Summary

| Field | Value | Source |
|---|---|---|
| Price | $86.36 (▲ 1.15%) | fmp:quote |
| Market Cap | $69.3B | fmp:profile |
| 52w range | $74.55 – $99.33 | fmp:quote |
| Earnings | Fri 7 Aug | fmp:earnings-history |
| EPS estimate | $0.97 (+5% YoY) | fmp:earnings-estimate |
| Revenue estimate | $5.3B | fmp:earnings-estimate |
| Beat streak | 8/4 | fmp:earnings-history |
| Rating | B+ (overall 3/5) | fmp:ratings |
| Analyst median target | $100 (+15.2% upside) | fmp:price-target-consensus |
| MoonshotScore | 49/100 | derived |
| Council | 2/6 bullish | derived |
| Munger verdict | Fairly Valued | derived |

## Colgate-Palmolive Company — Q1 FY2027 Expectations

Q1 consensus: revenue <strong data-source="fmp:earnings-estimate" data-field="estimates.next.revenueAvgLabel">$5.3B</strong><sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.revenueAvg" title="FMP est">[FMP est]</sup>, EPS <strong data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg">$0.97</strong><sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg" title="FMP est">[FMP est]</sup>. 8 consecutive quarters of beat<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.beatStreakCount" title="FMP earnings">[FMP earnings]</sup>.

## Quick Take

**Score:** B+ · **Stance:** BUY · **Council:** 2/6 · **Moonshot:** 49

= MoonshotScore <strong>49</strong><sup class="cite" data-source="derived" data-field="moonshot.score" title="9-pillar formula">[9-pillar formula]</sup> + Council <strong>2/6</strong><sup class="cite" data-source="derived" data-field="council.bullishCount" title="6-lens rule">[6-lens rule]</sup>. Form 4: 0 transactions<sup class="cite" data-source="fmp:insider-trading" data-field="insider.txCount" title="FMP Form 4">[FMP Form 4]</sup>.

## Watchlist (4 metrics)

### 1. 2027 2028 Savings Target

Colgate-Palmolive updated its strategic growth and productivity program with an annualized savings target of $200 million to $300 million, with the majority of the savings focused in 2027 and 2028.

> "This morning, we announced an update along with annualized savings target of $200 million to $300 million, with the majority of the savings focused in 2027 and 2028."
> — Noel Wallace, Investor Focus · Q1 FY2026

### 2. Emerging Markets Growth

Colgate-Palmolive expects growth in emerging markets, where its strong global brands generally have higher market shares and scale advantages, and is investing in them accordingly.

> "Our sales growth was led by emerging markets, the regions where our strong global brands generally have higher market shares and the greatest scale advantages. We believe emerging markets are accretive in terms of growth prospects and are investing in them accordingly."
> — Noel Wallace, Investor Focus · Q1 FY2026

### 3. Oil Price Assumption

Colgate-Palmolive is assuming oil at roughly $110 a barrel for the remainder of the year, impacting raw material and logistics costs.

> "We're assuming oil roughly at around $110."
> — Noel Wallace, Investor Focus · Q1 FY2026

### 4. North America Strategy Reset

Colgate-Palmolive is implementing a strategy reset in North America that includes brand interventions, accelerated innovation, better RGM, and promotion strategies.

> "That's going to include some real brand interventions, accelerated innovation, more RGM, better execution, getting our promotion strategy right with some of the key retailers."
> — Noel Wallace, Investor Focus · Q1 FY2026


## MoonshotScore Pillars

| Pillar | Score | Level | Evidence |
|---|---|---|---|
| Revenue Growth | 2.0 | weak | Q1 vs Q2: moderate growth (+4.2%) |
| Gross Margin | 6.0 | medium | Q1: high margin (60.6%) |
| Operating Leverage | 2.0 | weak | op margin healthy (21.7%) |
| Cash Runway | 10.0 | strong | FCF very strong ($0.6B, 4.4× CapEx) |
| R&D Intensity | 3.0 | weak | low R&D investment (0.0%, weak innovation) |
| Price Momentum | 4.0 | medium | RSI 53.1 balanced, 50d below |
| News Sentiment | 7.0 | strong | majority buy (65%) |

**Formula:** sum(pillar.score) / (count * 10) * 100. Each pillar deterministic from FMP. Source maps in pillar.formula.

## Council (7-Lens)

| Name | Stance | Context |
|---|---|---|
| Ray Dalio | bull | macro · target upside +15.2% |
| Ken Griffin | bear | flow · 50d MA below |
| Jim Simons | neutral | quant · RSI 53 |
| Klarman | neutral | value · target upside +15.2% |
| Buffett | bull | quality · ROE score 5/5 |
| Munger | neutral | valuation · target upside +15.2% |

**Formula:** Each lens uses deterministic rule on bundle data. Logged in member.contextTr.

## Munger Lens

- **Verdict:** Fairly Valued
- **Financial Health:** Moderate
- **Margin of Safety:** Moderate
- **Interest Coverage:** Adequate
- **ROIC vs WACC:** Healthy

**Formula:** verdict=upside>25?Undervalued:>0?Fairly Valued:Overvalued. Each lens deterministic from FMP ratings + priceTarget.

## Technical Levels

- **RSI(14):** 53.1 — dengeli — yön sinyali zayıf
- **50d MA:** $88 — hisse %1.4 altında — kısa vadeli direnç
- **200d MA:** $84 — hisse %3.0 üstünde — uzun vadeli destek
- **Volume (10d):** -71%

## Past Performance (4 Quarters)

| Quarter | EPS Actual | EPS Estimate | Result | Reaction |
|---|---|---|---|---|
| Q2 FY25 | $0.92 | $0.90 | BEAT | -0.2% |
| Q3 FY25 | $0.91 | $0.89 | BEAT | -2.7% |
| Q4 FY25 | $0.95 | $0.91 | BEAT | +1.8% |
| Q1 FY26 | $0.97 | $0.94 | +2.9% EPS | -2.2% |

Q1 (May 1, 2026): EPS $0.97 vs $0.94 est<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.history.0" title="FMP">[FMP]</sup>, +2.9% beat. D+1 movement: -2.2%<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.timeline.3.reactionLabel" title="FMP D+1">[FMP D+1]</sup>. Decline despite beat — market reacted to guidance, not numbers.

## 3 Scenarios

### Scenario A · Beat
**Q1 EPS > $0.97 + CapEx discipline**

Threshold: EPS > $0.97<sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg">[FMP est]</sup>.

Target: Break above median target $100<sup class="cite" data-source="fmp:price-target-consensus" data-field="priceTarget.median">[FMP target]</sup>; high target $102<sup class="cite" data-source="fmp:price-target-consensus" data-field="priceTarget.high">[FMP]</sup> upper bound.

### Scenario B · In-Line
**EPS ≈ $0.97 + CapEx < $138.0M**

Threshold: EPS ≈ $0.97<sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg">[FMP est]</sup>, Q1 CapEx < $138.0M<sup class="cite" data-source="fmp:cashflow" data-field="cashflow.qPrev.capexLabel">[FMP]</sup>.

Target: Consolidation in the band between current $86<sup class="cite" data-source="fmp:quote" data-field="quote.price">[FMP]</sup> and median $100<sup class="cite" data-source="fmp:price-target-consensus" data-field="priceTarget.median">[FMP]</sup>.

### Scenario C · Miss
**EPS < $0.94 or CapEx ≥ $138.0M**

Threshold: EPS < $0.94<sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg">[FMP est×0.97]</sup>.

Target: Current $86 below SMA200 $84<sup class="cite" data-source="fmp:technical" data-field="technical.sma200">[FMP]</sup>, if rejection continues, $71<sup class="cite" data-source="derived" data-field="technical.sma200" data-formula="round(sma200*0.85)">[derived]</sup> support activates.

## Risk Notes

### Primary segment below threshold
Q1: EPS $0.97 vs $0.94 beat<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.history.0" title="FMP">[FMP]</sup>, stock -2.2% D+1<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.timeline.3.reactionLabel" title="FMP">[FMP]</sup>.

### Backlog concentration
No RPO/backlog concentration disclosed in Q1 earnings call.

### Insider trading
Form 4 data is marked in the table — this page does not generate assumptions for this stock.

| Executive | Action | Amount | Date |
|---|---|---|---|


**Net:** — (0 transactions · 0 sells · 0 buys) · Q1 FY26

### CapEx shock
Q1 CapEx $138.0M<sup class="cite" data-source="fmp:cashflow" data-field="cashflow.qPrev.capexLabel" title="FMP cashflow">[FMP cashflow]</sup>. Q1 op margin 21.7%<sup class="cite" data-source="fmp:income" data-field="income.quarters.0.operatingMargin" title="FMP op margin">[FMP op margin]</sup> — this level in Q1 is sensitive to CapEx revision risk.

## Wall Street Consensus

- **Median target:** $100 (+15.2% upside vs current $86)
- **High / Low:** $102 / $79
- **Buy / Hold / Sell:** 13 / 7 / 0
- **Analyst count:** 9 (last quarter), 62 all-time

## Additional Transcript Insights

### 1. emerging_markets_growth

**Claim:** Colgate-Palmolive expects growth in emerging markets, where its strong global brands generally have higher market shares and scale advantages, and is investing in them accordingly.

**Evidence (transcript):** "Our sales growth was led by emerging markets, the regions where our strong global brands generally have higher market shares and the greatest scale advantages. We believe emerging markets are accretive in terms of growth prospects and are investing in them accordingly."

**Numbers:** —

### 2. 2027_2028_savings_target

**Claim:** Colgate-Palmolive updated its strategic growth and productivity program with an annualized savings target of $200 million to $300 million, with the majority of the savings focused in 2027 and 2028.

**Evidence (transcript):** "This morning, we announced an update along with annualized savings target of $200 million to $300 million, with the majority of the savings focused in 2027 and 2028."

**Numbers:** $200 million, $300 million, 2027, 2028

### 3. oil_price_assumption

**Claim:** Colgate-Palmolive is assuming oil at roughly $110 a barrel for the remainder of the year, impacting raw material and logistics costs.

**Evidence (transcript):** "We're assuming oil roughly at around $110."

**Numbers:** $110

### 4. north_america_strategy_reset

**Claim:** Colgate-Palmolive is implementing a strategy reset in North America that includes brand interventions, accelerated innovation, better RGM, and promotion strategies.

**Evidence (transcript):** "That's going to include some real brand interventions, accelerated innovation, more RGM, better execution, getting our promotion strategy right with some of the key retailers."

**Numbers:** —


---

*Data source: FMP (live query, 2026-05-05), Q1 FY2026 earnings call transcript (Translated to EN with Gemini 2.0 Flash). Educational tool, not investment advice.*